1 min read

ID: 54

Short Link: https://gregory-ms.com/articles/54/

Discovery Date: 24 February 2021, 11:11:00 UTC

Published Date: 2021-01-03 00:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/33621404/?fc=20210216052009&ff=20210223200936&v=2.1

Manual Selection: none

Machine Learning Gaussian Naive Bayes Model: false


Ann Clin Transl Neurol. 2021 Feb 23. doi: 10.1002/acn3.51310. Online ahead of print.


The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N = 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions occurred in 12.4% of patients. None were severe, life-threatening or led to treatment discontinuation. Shorter infusion time did not change the safety profile of OCR. Clinicaltrials.gov (NCT0237856).

PMID:33621404 | DOI:10.1002/acn3.51310

Noun Phrases in Title

  • Safety evaluation
  • shorter infusion
  • ocrelizumab
  • a substudy
  • the Phase IIIb CHORDS trial
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.